Sponsor:
CHU de Quebec-Universite Laval
Code:
NCT03314025
Conditions
Urinary Retention
Eligibility Criteria
Sex: Male
Age: 18+
Healthy Volunteers: Accepted
Interventions
Tamsulosin Hydrochloride 0.4 MG
Placebo oral capsule
Foley catheter
Brief summary:
Conditions
Urinary Retention
Study ID
NCT03314025
Start date
Oct 6, 2017
Status verified date
May, 2021
Completion date
Oct 1, 2022
Anticipated
Primary completion date
Oct 1, 2022
Anticipated
Eligibility Criteria
Sex: Male
Age: 18+
Healthy Volunteers: Accepted
Enrollment
158 participants
Anticipated
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary purpose
Prevention
Arms
experimental: Tamsulosin
placebo comparator: Placebo
Interventions
Tamsulosin Hydrochloride 0.4 MG
Placebo oral capsule
Foley catheter
Primary outcome measure
Central contacts
Locations
CHU de Quebec - Universite Laval
Recruiting
Quebec City, Quebec, Canada, G1L 3L5
Contacts
Principal Investigator:
Sebastien Drolet, MD FRCSC
Sponsor
CHU de Quebec-Universite Laval
Last update posted
May 19, 2021
Last verified
May, 2021
Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by CHU de Quebec-Universite Laval on 2021-05-19.